·维勒布兰德因子作为血栓性疾病的治疗标
Yvonne K Jongejan1, Bart J M van Vlijmen1, Jeroen C J Eikenboom1
1Division of Thrombosis and Hemostasis, Department of Internal Medicine, Einthoven Laboratory for Vascular and Regenerative Medicine, Leiden University Medical Center, Leiden, The Netherlands.
Thrombosis and haemostasis
|August 11, 2025
概括
针对·威尔布兰德因子 (VWF) 为血栓形成提供了一种新的治疗策略,独立于血小板路径. 本综述详细介绍了VWF抑制剂的使用情况.
科学领域:
- 血液静止和血栓形成研究
- 药理学和药物开发领域
背景情况:
- ·威尔布兰德因子 (VWF) 对于初级静血至关重要.
- 变化的VWF水平与出血障碍 (如·威勒布兰德病) 和动脉血栓形成风险有关.
- 目前针对血小板聚合的抗血小板疗法存在局限性,需要采用替代方法.
研究的目的:
- 提供针对·威尔布兰德因子 (VWF) 的治疗药物的全面审查.
- 阐明VWF抑制剂的进化,发育阶段和临床应用.
- 评估现有和新兴的VWF向疗法的优点和局限性.
主要方法:
- 在血栓形成管理中对VWF抑制剂的文献综述.
- 临床进展和应用VWF向剂的分析.
- 治疗疗效,安全性和限制的评估.
主要成果:
- 几种VWF抑制剂已进入用于血栓形成的临床应用.
- 目前正在进行的研究重点是针对VWF的新型化合物.
- 抑制VWF提供了与血小板聚合抑制剂的替代方案.
结论:
- 向VWF是一种有前途的血栓治疗策略,独立于血小板激活.
- VWF抑制剂呈现出一种不断发展的抗血栓剂类,具有独特的临床特征.
- 进一步的研究和开发对于优化VWF向疗法至关重要.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
903
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
903
Venous Thrombosis III: Interprofessional Care
22
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
22
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
Clot Retraction and Fibrinolysis
6.8K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.8K
Extrinsic and Intrinsic Pathways of Hemostasis
9.2K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
9.2K
Disorders of Hemostasis
1.2K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
1.2K


